VBL Therapeutics to Present Interim Phase 2 Data From

New Post Public Reply Private Reply Replies (0) Message Board
News Desk 2018
VBL Therapeutics to Present Interim Phase 2 Data From VB-111 in Recurrent Glioblastoma at 19th Annual Scientific Meeting of the Society for Neuro-Oncology (SNO)

-- Interim Data Suggest Improved Overall Survival in Patients Treated With VB-111 in Combination With Bevacizumab (Avastin®) --

TEL AVIV, Israel, Nov. 13, 2014 (GLOBE NEWSWIRE) -- VBL Therapeutics (Nasdaq: VBLT ), a clinical-stage biotechnology company committed to the discovery, development and commercialization of first-in-class treatments for cancer and immune-inflammatory diseases, today announced positive preliminary results from its ongoing Phase 2 trial of VB-111 in patients with recurrent glioblastoma (rGBM). Improved overall survival was suggestive in patients with rGBM who received VB-111 as a standalone drug and who, upon further progression, were treated with VB-111 in combination with bevacizumab (Avastin®) compared to patients treated with bevacizumab alone upon further progression. These study results will be presented at the 19 th Annual Scientific Meeting and Education Day of the Society for Neuro-Oncology (SNO) on November 14, 2014, at 4:30 pm ET, in Americana 3 at the Loews Hotel in Miami, Florida.

"These early clinical data with VB-111 in patients with recurrent GBM, are exciting and demonstrate the potential of the compound's novel mechanism of action and innovative gene therapy approach," said principal investigator, Andrew Brenner, MD, PhD, Clinical Investigator with the Cancer Therapy and Research Center at the University of Texas Health Science Center San Antonio. "The survival benefit trend seen in patients who continued on a combination regimen with VB-111 is promising, underscores the need for novel approaches to this debilitating disease, and highlights the potential for this drug to make a difference for our patients."

"We are pleased by these interim results and are excited to see increased survival in patients on VB-111," said Dror Harats, MD, Chief Executive Officer of VBL Therapeutics. "These preliminary results are particularly encouraging because, in this trial both longer exposure to VB-111 and combining VB-111 and bevacizumab led to an increase in median overall survival compared to treatment with bevacizumab alone, without safety or tolerability concerns.  We look forward to advancing VB-111 into a pivotal Phase 3 clinical trial in 2015."

The interim Phase 2 data for VB-111 were presented for 46 patients with rGBM treated with VB-111; upon further progression, 23 of them were treated with VB-111 in combination with bevacizumab, and 23 received bevacizumab alone. VB-111 in combination with bevacizumab demonstrated a numerically improved median overall survival of 504 days, compared to 235 days in patients on VB-111 followed by bevacizumab alone. Tumor response data, available for 15 of the patients who received VB--111 in combination with bevacizumab, showed stable disease or better in 12 patients (80%), reduction of at least 25% in RANO score in nine patients (60%) and partial response, defined by at least 50% reduction in tumor mass, in 3 patients (20%). The Company believes that this decrease in tumor mass and the subsequent increase in overall survival resulted from either increased exposure to VB-111 and/or a synergistic effect of VB-111 combined with bevacizumab, and support the design of VBL's pivotal Phase 3 study, set to begin in the first half of 2015 under a special protocol assessment agreement granted by the FDA.

In this study, VB-111 was safe and well-tolerated both as a monotherapy and in combination with bevacizumab. Most adverse events observed in the study were low-grade flu-like symptoms, including fever and chills, which occurred on the day of treatment at approximately six hours after infusion, and were transient and controlled with anti-fever medications.

This Phase 1/2 trial is a multi-center, two stage, dose-escalation study designed to determine the safety, tolerability and efficacy of VB-111 in patients with rGBM. In the first phase of the study, patients were treated with VB-111 alone. Upon disease progression, defined as a worsening of the patient's cancer with an increase of at least 25% in the overall mass of measurable tumors, the appearance of new tumors, the worsening of non-measurable tumors since the beginning of treatment, a need for increased dose of corticosteroids, or clinical deterioration, patients received either bevacizumab alone or bevacizumab in combination with VB-111.

About VB-111:

VB-111 is a novel, intravenously-administered, anti-angiogenic agent that utilizes VBL's proprietary Vascular Targeting System (VTS™) to target endothelial cells in the tumor vasculature for cancer therapy. VB-111 contains a non-replicating adenovector, a proprietary modified murine pre-proendothelin promoter (PPE-1-3x) and a Fas-Chimera transgene to angiogenic tumor blood vessels, leading to their apoptosis. VB-111 is the first agent based on transcriptional targeting of tumor endothelium to be assessed in a clinical trial.

VB-111 completed a Phase 1/2 "all comers" clinical trial, which demonstrated multiple cases of objective tumor response and disease control and excellent safety and tolerability. VB-111 has Fast Track Designation for recurrent glioblastoma in the US, and orphan drug status for glioblastoma in both the US and EU. VB-111 has also been advanced into tumor specific, repeat-dose trials in thyroid and ovarian cancer.

About VBL:

Vascular Biogenics Ltd., operating as VBL Therapeutics, is a clinical-stage biopharmaceutical company committed to the discovery, development and commercialization of first-in-class treatments for cancer and immune-inflammatory diseases. VBL Therapeutics' clinical pipeline is based on two distinct, proprietary platform technologies—an oncology program and an anti-inflammatory program—that leverage the body's natural physiologic and genetic regulatory elements. The Company's lead oncology product candidate, VB-111, is a gene-based biologic that is initially being developed for recurrent glioblastoma, or rGBM, an aggressive form of brain cancer. VB-111 has received orphan drug designation in both the United States and Europe and was granted Fast Track designation by the FDA for prolongation of survival in patients with glioblastoma that has recurred following treatment with standard chemotherapy and radiation. VBL Therapeutics expects to begin the pivotal Phase 3 trial for VB-111 in rGBM in the first half of 2015, under a special protocol assessment agreement granted by the FDA. VBL Therapeutics' lead product candidate from its anti-inflammatory program, VB-201, is an oral small molecule currently being evaluated in Phase 2 clinical trials for psoriasis and for ulcerative colitis, with top-line results expected in the first quarter of 2015.

Forward-Looking Statements:

This press release contains forward-looking statements. These forward-looking statements are not promises or guarantees and involve substantial risks and uncertainties. Among the factors that could cause actual results to differ materially from those described or projected herein include uncertainties associated generally with research and development, clinical trials and related regulatory reviews and approvals, and the risk that historical clinical trial results may not be predictive of future trial results. A further list and description of these risks, uncertainties and other risks can be found in the Company's regulatory filings with the U.S. Securities and Exchange Commission. Existing and prospective investors are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof. VBL Therapeutics undertakes no obligation to update or revise the information contained in this press release, whether as a result of new information, future events or circumstances or otherwise.

Paul Cox Stern Investor Relations, Inc. (212) 362-1200,

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Peñoles Locks In Solar Storage for Northern Mine Loads

Updated Category News Views 33

A mine never sleeps, which is why the battery matters more than the solar-panel headline. Peñoles has signed a 20-year power-supply agreement with Atlas Renewable Energy for a Coahuila project combining 269 MWp of solar generation with battery storage. The project is slated to begin operating in the first half of 2029 and is expected to provide roughly 550 GWh a year to...

Continue Reading
Tonum and Euvita Link Supplements to Personalized Care

Updated Category News Views 14

Muscle loss has become the awkward footnote in the GLP-1 weight-loss boom, and Tonum Health is trying to put that concern nearer the center of the care conversation. Its newly announced partnership with euvita health places Tonum's supplements and functional nutrition products inside a physician-led platform built around biomarker testing, hormone and peptide therapy,...

Continue Reading
Blue Diamond's $1 Billion Brand Meets Farm Realities

Updated Category News Views 76

A Ten-Cent Signal Carries Real Weight A ten-cent edge over the industry benchmark may not excite the cocktail-party crowd, but almond growers notice every penny when fertilizer, power and pest control keep gnawing at the farm gate. Blue Diamond Growers says it delivered payments roughly 10 cents above the benchmark in its latest year, alongside net profit that came in...

Continue Reading
Italian Wine Faces U.S. Slump and New Market Openings

Updated Category News Views 110

American demand has put a cork in the easy story, and Italian wine producers cannot pretend otherwise. In the first nine months of 2026, U.S. imports of Italian wine dropped 18.4% by value. That is painful because the United States remains Italy's largest destination market by value, not some side shelf that can be ignored until conditions improve. Still, the broader U.S....

Continue Reading
Dario’s Second Women’s Health Win Tests Expansion Case

Updated Category News Views 71

Midlife care just became the newest proving ground for DarioHealth’s sales pitch. The company says The Minnesota Star Tribune has expanded its existing relationship to include Dario Women™, a program for employees navigating perimenopause and menopause. Eligible employees are expected to gain access in January 2027. For NASDAQ:DRIO, this is not some grand revenue...

Continue Reading
Hone Health’s $228M Bet on Data-Led Longevity Care

Updated Category News Views 172

Longevity medicine just got a very large check and an even larger assignment. Hone Health says it has raised $228 million to push physician-led care beyond its roots in hormone optimization, and the split of that financing matters more than the celebrity names attached to it. Only $28 million is described as Series A equity; the other $200 million comes as growth...

Continue Reading
MIND Takes Its Copilot Security Bet Across Microsoft 365

Updated Category News Views 59

Copilot’s promise gets a lot less charming the minute confidential files start wandering around unchecked. That is the knot MIND is trying to untie with its expanded, generally available integrations across Microsoft Copilot, Microsoft 365, Purview, Teams, SharePoint, OneDrive, Edge and Exchange. The Seattle data-loss-prevention company announced the collaboration on...

Continue Reading
Devicie Broadens Browser Security Across Device Fleets

Updated Category News Views 23

Browsers have quietly become the front door, side door, and occasionally the busted basement window of corporate security. Devicie’s newly expanded Edge for Business Reporting Connector tackles that uncomfortable reality by pulling browser security events from Windows, macOS, iOS, and Android into the same console customers use to oversee Microsoft Intune environments....

Continue Reading
Another Nine's A9OS Puts Software at Center of Golf

Updated Category News Views 63

A golf simulator chain is trying to turn the boring plumbing into its sharpest club. Another Nine’s A9OS is not merely a booking widget dressed up for a franchise brochure; it is meant to run the whole 24/7 operation, from payments and door access to cameras, simulator support and guest help. That ambition deserves attention because this is exactly where a staff-free...

Continue Reading
SteriLance Aims for Smoother Pricks with NanoSense Move

Updated Category News Views 92

Revamping the Lancing Game Out there in Suzhou, SteriLance Medical is steering clear of just chasing meter accuracy—do enough folks even care about glorified electronics?—they're zeroing in on the needle part of the blood glucose test, the part that pricks your finger every damn day. Yep, this new initiative is inviting blood glucose monitoring (BGM) brands to embrace...

Continue Reading

Top 5 Most Recently Viewed Articles

Gamma Communications Celebrated for UCaaS Competitive Strategy

Updated Category News Views 342

Gamma Communications Receives Frost & Sullivan Recognition Gamma Communications has received prestigious recognition from Frost & Sullivan with the 2024 Competitive Strategy Leadership Award in the European unified communications as a service (UCaaS) industry. This award highlights the company’s exceptional strategy execution, innovative approaches, and impressive...

Continue Reading
ConocoPhillips Reports Strong Q3 2025 Results and Outlook

Updated Category News Views 232

ConocoPhillips Delivers Strong Third Quarter Performance ConocoPhillips (NYSE: COP) has once again demonstrated its robust operational capacity, reporting impressive financial results for the third quarter. Beginning with consistent execution across its production portfolio, the company's recent performance has exceeded market expectations, showcasing a continued...

Continue Reading
Electrosurgery Generators Market Set to Surge by $3.3 Billion

Updated Category News Views 125

Electrosurgery Generators Market Overview The global electrosurgery generators market is on an impressive growth trajectory, projected to reach USD 3,359.2 million by 2035. As healthcare evolves, this market is driven by innovations and a rising preference for minimally invasive procedures. The surge in outpatient surgical centers and advancements in electrosurgical...

Continue Reading
Explore the Versatile Applications of INNOVERA™ at Lineapelle Milan

Updated Category News Views 322

Discover INNOVERA™ at Lineapelle Milan 2026 Modern Meadow, a pioneer in bio-design, is set to showcase their groundbreaking material, INNOVERA™, at the highly anticipated Lineapelle Milan 2026. This prominent international leather fair will provide a platform for the company to illustrate the dynamic capabilities of INNOVERA™ across various industries. A Revolution...

Continue Reading
Harnessing AI for Enhanced Military Logistics Efficiency

Updated Category News Views 174

Virtualitics Secures Phase II Contract with AFGSC Virtualitics has recently been awarded a significant contract with the U.S. Air Force Global Strike Command (AFGSC). This Small Business Innovation Research (SBIR) Phase II contract aims to optimize logistics using artificial intelligence (AI) for Readiness Spares Package (RSP) mobilization. This initiative is crucial to...

Continue Reading